Ioxilan

Clinical data
Trade names	Oxilan
AHFS/Drugs.com	FDA Professional Drug Information
Routes of administration	intravenously
ATC code	V08AB12 (WHO)
Legal status
Legal status	US: ℞-only Discontinued
Pharmacokinetic data
Bioavailability	N/A
Protein binding	negligible
Metabolism	none
Elimination half-life	2 hours
Excretion	Mostly renal
Identifiers
IUPAC name 1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number	107793-72-6 N
PubChem CID	3743
DrugBank	DB09135 Y
ChemSpider	3612 Y
UNII	A4YJ7J11TG
KEGG	D02161 Y
ChEMBL	ChEMBL1201075 N
CompTox Dashboard (EPA)	DTXSID0048717
Chemical and physical data
Formula	C18H24I3N3O8
Molar mass	791.112 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
InChI InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32) Y Key:UUMLTINZBQPNGF-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Ioxilan is a diagnostic contrast agent.^[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but has been discontinued in 2017.^[2]

Mechanism of action

Ioxilan is an iodinated contrast agent.^[2]